Anthem Biosciences Q1 FY27 Revenue ₹418 Cr, PAT ₹120 Cr

Unit 1 (Custom Synthesis): Utilization at ~78% (similar to last year's 74%).
Unit 2 (Custom Synthesis): Utilization at ~50% for the quarter (down from 65% last full year) due to a recent 130 kiloliter expansion and softer quarter.
Unit 2 (Fermentation): Utilization at ~50% across 140 kiloliters capacity.
Unit 3 (Neo Anthem): Utilization ramped up to 30-35% in Q1 FY27 from ~15% in FY26. The unit houses modern pilot plants, peptide synthesis, and oncology manufacturing.

Management expressed confidence in achieving growth "in line with our long-term historical performance" and "double-digit growth" for FY27.
The company has 60% visibility for FY27 revenues based on its current order book, which has been replenished post-Q1.
Q1 was described as the "softest quarter for the year," with growth expected to recover in Q2, Q3, and Q4. This is attributed to customer deferrals of deliveries to later quarters.
The lumpy nature of the CRDMO business, dependent on customer delivery schedules, was emphasized, advising investors to focus on YoY performance rather than QoQ.

Project: Unit 4 Phase 1 expansion.
Capacity Addition: 365 kiloliters of custom synthesis and 100 kiloliters of fermentation. A food and nutra plant is also being added.
Total Capex Outlay: ₹1,200 crores.
Spend Phasing: ~₹700 crores targeted for FY27, with a similar amount expected in FY28 (50-50 split).
Timeline: Construction is underway. Commissioning is expected by the end of FY28.
Purpose: To accommodate growth from existing commercial molecules and the pipeline of 10 late-phase molecules.

New Client: The company is in advanced discussions to onboard a new Big Pharma client, with a multi-dimensional engagement (R&D, new projects, supply chain diversification) expected to contribute in the "later quarters of this year."
Project Pipeline: The company has 100+ early-stage development programs and 10 molecules in late-phase development. The path to commercialization for late-phase molecules is typically 18-24 months.
Modalities: The pipeline includes a couple of ADC molecules in late phase and peptide molecules in early stages.
Recent Commercialization: Four new molecules were commercialized by customers in the previous year (FY26).

Status: Awaiting commercial approval from CDSCO. Development and scale-up trials are complete.
Market: Initially focused on the domestic market. The company has sampled "almost all the big players" in India.
Outlook: Approval and subsequent commercial supply are expected "sometime this year" or "in a quarter or two."

Management expressed confidence in sustaining the current industry-leading margin profile (~40% EBITDA, ~27% PAT) through FY27, backed by the strong order book.
Long-term margin sustainability is attributed to a focus on technology, innovation, flow chemistry, bio-catalysis, yield optimization, and cost efficiencies.
ESOP Cost: FY27 ESOP cost is estimated at ₹9 crores (₹2.25 cr in Q1), down from ₹16 crores in FY26. This is expected to decline further to ~₹5 crores in FY28.
Tax Rate: The tax rate is expected to normalize to ~25-25.5% for FY27, as losses in the Unit 3 (Neo Anthem) subsidiary are expected to reduce.

Customer M&A: A biotech customer was acquired by a Big Pharma company. The impact is not material for FY27, as integrations typically take 1-2 years. This is seen as a long-term opportunity to deepen ties with the acquiring Pharma major.
Working Capital: No significant changes reported. Some inventory build-up was noted due to raw material procurement for Q2 and Q3 deliveries.
AI Strategy: The company is evaluating AI use cases for document review, manufacturing optimization, and predictive chemistry. It is seen as a long-term evolution that could ultimately benefit demand for CRDMO services.